Sarepta Therapeutics, Inc. cotiza a 17.44 USD y tiene una capitalización bursátil de $1.8B. En los últimos 12 meses ha facturado $2.0B con un margen de flujo de caja libre del -14.0%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who h…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $0.64 | $3.16 | $-3.58 |
| Estimado | $0.36 | $0.49 | $1.05 | $-0.77 |
| Sorpresa | — | +30.6% | +201.0% | -364.9% |
| Métrica | SRPT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 98.8% | 57.0% | +41.8% |
| Operating Margin | -31.8% | -38.6% | +6.8% |
| Net Margin | -32.5% | -33.6% | +1.1% |
| FCF Margin | -14.0% | -13.9% | -0.1% |
| ROE | -62.5% | -40.4% | -22.1% |
| ROA | -21.3% | -32.0% | +10.7% |
| Current Ratio | 2.32 | 2.84 | -0.52 |
| Debt / Equity | 0.73 | 0.28 | +0.45 |